• Dépistage, diagnostic, pronostic

  • Découverte de technologies et de biomarqueurs

  • Autres organes

Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer

Menée sur 213 hommes infectés par le VIH et ayant des relations sexuelles avec des hommes, cette étude met en évidence une association entre la vitamine B12 et la succinyl-CoA issues du microbiome et la présence, au niveau de l'anus, de lésions épidermoïdes intraépithéliales de haut grade

Human papillomavirus can cause preinvasive, high-grade squamous intraepithelial lesions (HSILs) as precursors to cancer in the anogenital area, and the microbiome is suggested to be a contributing factor. Men who have sex with men (MSM) living with human immunodeficiency virus (HIV) have a high risk of anal cancer, but current screening strategies for HSIL detection lack specificity. Here, we investigated the anal microbiome to improve HSIL screening. We enrolled participants living with HIV, divided into a discovery (n = 167) and validation cohort (n = 46), and who were predominantly (93.9%) cisgender MSM undergoing HSIL screening with high-resolution anoscopy and anal biopsies. We identified no microbiome composition signatures associated with HSILs, but elevated levels of microbiome-encoded proteins producing succinyl coenzyme A and cobalamin were significantly associated with HSILs in both cohorts. Measurement of these candidate biomarkers alone in anal cytobrushes outperformed anal cytology as a diagnostic indicator for HSILs, increasing the sensitivity from 91.2% to 96.6%, the specificity from 34.1% to 81.8%, and reclassifying 82% of false-positive results as true negatives. We propose that these two microbiome-derived biomarkers may improve the current strategy of anal cancer screening.

Nature Medicine , résumé, 2023

Voir le bulletin